Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara.
The production of several viral vaccines depends on chicken embryo fibroblasts or embryonated chicken eggs. To replace this logistically demanding substrate, we created continuous anatine suspension cell lines (CR and CR.pIX), developed chemically-defined media, and established production processes for different vaccine viruses. One of the processes investigated in greater detail was developed for modified vaccinia virus Ankara (MVA). MVA is highly attenuated for human recipients and an efficient vector for reactogenic expression of foreign genes. Because direct cell-to-cell spread is one important mechanism for vaccinia virus replication, cultivation of MVA in bioreactors is facilitated if cell aggregates are induced after infection. This dependency may be the mechanism behind our observation that a novel viral genotype (MVA-CR) accumulates with serial passage in suspension cultures. Sequencing of a major part of the genomic DNA of the new strain revealed point mutations in three genes. We hypothesize that these changes confer an advantage because they may allow a greater fraction of MVA-CR viruses to escape the host cells for infection of distant targets. Production and purification of MVA-based vaccines may be simplified by this combination of designed avian cell line, chemically defined media and the novel virus strain.
ProBioGen AG, Goethestr. 54, 13086 Berlin, Germany. ingo.jordan@probiogen.de.
Ingo
I
Jordan
ProBioGen AG, Goethestr. 54, 13086 Berlin, Germany. verena.lohr@probiogen.de.
Verena
V
Lohr
Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstr. 1, 39106 Magdeburg, Germany. genzel@mpi-magdeburg.mpg.de.
Yvonne
Y
Genzel
Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstr. 1, 39106 Magdeburg, Germany. ureichl@mpi-magdeburg.mpg.de.
Udo
U
Reichl
ProBioGen AG, Goethestr. 54, 13086 Berlin, Germany. volker.sandig@probiogen.de.
Volker
V
Sandig
AGE1.CR.pI; MVA (modified vaccinia virus Ankara); modified vaccinia virus Ankara; muscovy duck continuous cell line
J Exp Biol. 2003 Nov;206(Pt 21):3771-9
14506212
J Virol. 1993 Jun;67(6):3319-25
8497053
PLoS One. 2013 Sep 05;8(9):e72288
24039749
J Virol. 1997 Apr;71(4):3005-12
9060660
J Virol. 1987 Mar;61(3):787-95
3027405
Dtsch Med Wochenschr. 1974 Nov 22;99(47):2386-92
4426258
Expert Rev Vaccines. 2009 May;8(5):577-92
19397415
Viruses. 2013 Jan 21;5(1):321-39
23337383
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2772-7
15699328
J Gen Virol. 1998 May;79 ( Pt 5):1159-67
9603331
Clin Cancer Res. 2004 May 1;10(9):2986-96
15131034
J Gen Virol. 2004 Aug;85(Pt 8):2167-75
15269355
Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4894-9
15044706
Science. 2004 Oct 15;306(5695):385
15486259
Oncogene. 2005 Nov 21;24(52):7673-85
16299528
Biochem Pharmacol. 2008 Feb 1;75(3):589-602
17868652
J Virol. 2000 Oct;74(20):9701-11
11000242
Vaccine. 1994 Aug;12(11):1032-40
7975844
Biotechnol Prog. 2004 May-Jun;20(3):858-63
15176892
J Virol. 1996 Jan;70(1):272-81
8523536
Comp Immunol Microbiol Infect Dis. 2003 Oct;26(5-6):423-30
12818626
J Gen Virol. 2007 Dec;88(Pt 12):3249-59
18024893
Biotechnol Bioeng. 2013 Oct;110(10):2633-42
23568808
Vaccine. 2010 Apr 26;28(19):3308-11
20226252
Nat Genet. 2013 Jul;45(7):776-83
23749191
Vaccine. 2013 Sep 6;31(39):4247-51
23523407
Clin Vaccine Immunol. 2009 Dec;16(12):1709-19
19793898
Public Health. 2008 Feb;122(2):183-91
17825858
Nat Rev Mol Cell Biol. 2002 Jun;3(6):441-52
12042766
Curr Opin Biotechnol. 2007 Dec;18(6):546-56
18063357
Biologicals. 2011 Jan;39(1):50-8
21237672
Biotechnol Bioeng. 2010 Mar 1;105(4):761-9
19891005
J Virol. 2002 Mar;76(5):2206-16
11836398
J Gen Virol. 1992 Nov;73 ( Pt 11):2995-7
1331300
J Clin Invest. 2007 Dec;117(12):3958-70
18008010
Clin Vaccine Immunol. 2006 Jul;13(7):747-57
16829611
J Gen Virol. 1998 Feb;79 ( Pt 2):347-52
9472619
J Virol. 1998 Jul;72(7):5955-66
9621058
Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11178-92
15249657
Virol J. 2006 Oct 25;3:88
17062162
J Virol. 2002 Aug;76(16):8318-34
12134037
Wkly Epidemiol Rec. 1998 Jul 10;73(28):209-12
9677853
Infect Immun. 2002 Mar;70(3):1623-6
11854254
Cancer Immunol Immunother. 2010 Jun;59(6):863-73
20043222
Biotechniques. 1997 Dec;23(6):1094-7
9421642
J Gen Virol. 1991 May;72 ( Pt 5):1031-8
2033387
J Virol. 2005 Apr;79(8):4755-63
15795261
J Clin Oncol. 2010 Mar 1;28(7):1099-105
20100959
BMC Biotechnol. 2012 Oct 30;12:79
23110398
Curr Opin Immunol. 2009 Jun;21(3):346-51
19500964
Biol Direct. 2008 Mar 24;3:9
18361801
Clin Infect Dis. 1998 Nov;27(5):1194-200
9827268
Virology. 2007 Sep 30;366(2):424-32
17553539
Vaccine. 2000 May 8;18(22):2435-43
10738101
J Virol. 1997 Jul;71(7):5095-101
9188575
J Virol. 1975 Dec;16(6):1492-502
172655
Nature. 1970 Jul 11;227(5254):168-70
4316953
Bull N Y Acad Med. 1953 Dec;29(12):943-60
13106597
J Exp Med. 1937 May 31;65(6):787-800
19870634
J Virol. 2001 Jul;75(13):5778-95
11390580
Methods Mol Biol. 2012;890:59-92
22688761
Lancet. 2012 Dec 15;380(9859):2095-128
23245604
J Gen Virol. 2003 Jun;84(Pt 6):1383-92
12771405
Clin Diagn Virol. 1996 Feb;5(1):43-53
15566860
Biologicals. 1995 Sep;23(3):221-4
8527121
J Virol. 2002 Nov;76(22):11637-44
12388724
J Gen Virol. 2004 Jan;85(Pt 1):105-17
14718625
J Gen Virol. 1970 Oct;9(1):1-7
5529999
Biologicals. 2010 May;38(3):350-1
20335050
Vaccine. 2003 Oct 1;21(27-30):4105-17
14505886
Vaccine. 2009 Aug 6;27(36):4975-82
19531390
Zentralbl Bakteriol Orig. 1964 Dec;195(1):24-35
5890664
Vaccine. 2006 Jan 23;24(4):417-25
16176847
Biotechnol Bioeng. 2010 Oct 1;107(2):312-20
20506129
Clin Cancer Res. 2004 May 1;10(9):2905-7
15131023
Hum Gene Ther. 1998 Sep 1;9(13):1909-17
9741429
Virology. 2005 Oct 10;341(1):91-101
16061267
Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4836-41
15781866
Eff Clin Pract. 2002 Mar-Apr;5(2):84-90
11990216
Oncogene. 2010 Oct 14;29(41):5619-29
20676141
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10847-51
1438287
Vaccine. 2012 Apr 5;30(17):2715-27
22342707
J Exp Biol. 2011 Jun 1;214(Pt 11):1902-10
21562178
J Immunol. 2005 Jan 1;174(1):449-55
15611270
Virology. 1988 May;164(1):22-9
3363865
Gene. 1983 Nov;25(1):21-8
6229451
Amino Acids. 2011 Apr;40(4):1053-63
20697752
Comp Biochem Physiol B Biochem Mol Biol. 2003 Apr;134(4):543-58
12670782
Virology. 2004 Dec 5;330(1):127-46
15527840
J Gen Virol. 1995 Jan;76 ( Pt 1):1-13
7844518
J Virol. 2013 Jul;87(14):7992-8003
23678178
Vaccine. 2006 May 22;24(21):4554-61
16150517
Braz J Med Biol Res. 2012 Dec;45(12):1102-11
22948379
Biologicals. 1998 Sep;26(3):175-93
10208720
Vaccine. 2009 Jan 29;27(5):748-56
19071186
N Engl J Med. 2009 Dec 3;361(23):2209-20
19843557
Virology. 1997 Nov 24;238(2):198-211
9400593
J Virol. 2002 Sep;76(17):8973-6
12163618
Viruses. 2012 May;4(5):688-707
22754644
J Virol. 2003 Oct;77(19):10606-22
12970445
BMC Immunol. 2008 Apr 15;9:15
18412969
PLoS One. 2008;3(12):e3973
19096527
J Gen Virol. 1977 Jul;36(1):59-74
886304
Cancer Res. 1999 Oct 15;59(20):5106-11
10537283
Oncogene. 2002 Jan 24;21(5):748-60
11850803
Nature. 2001 Feb 15;409(6822):860-921
11237011
Cancer Gene Ther. 2013 Feb;20(2):70-6
23306610